| CRISPR-Cas3 induces broad and unidirectional genome editing in human cells H Morisaka, K Yoshimi, Y Okuzaki, P Gee, Y Kunihiro, E Sonpho, H Xu, ... Nature communications 10 (1), 5302, 2019 | 177 | 2019 |
| CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun 10: 5302 H Morisaka, K Yoshimi, Y Okuzaki, P Gee, Y Kunihiro, E Sonpho, H Xu, ... | 5 | 2019 |
| Keratinocyte regnase-1, a downregulator of skin inflammation, contributes to protection against tumor promotion by limiting cyclooxygenase-2 expression H Morisaka, M Takaishi, S Akira, S Sano Journal of Investigative Dermatology 143 (5), 731-739, 2023 | 4 | 2023 |
| Case of pigmented skin metastasis of breast carcinoma H Morisaka, R Nakajima, Y Aoyama, M Teraishi, H Nakajima, M Ogawa, ... The Journal of Dermatology 48 (9), e476-e477, 2021 | 4 | 2021 |
| Beneficial impact of apremilast on palmoplantar keratodermas K Nakajima, R Nakajima, H Morisaka, H Nakajima, S Shigetoshi Acta Dermato-Venereologica 101 (4), 2021 | 3 | 2021 |
| 490 Genome editing in mammalian cells by cascade and Cas3 H Morisaka, S Sano, J Takeda Journal of Investigative Dermatology 137 (5), S84, 2017 | 2 | 2017 |
| 356 Mechanisms of dermatitis development in Regnase-1 3’UTR mutant mice H Morisaka, K Maeda, M Fujimoto, S Akira Journal of Investigative Dermatology 144 (12), S289, 2024 | | 2024 |
| Method for producing dna-edited eukaryotic cell, and kit used in the same T Mashimo, J Takeda, H Morisaka, K Yoshimi US Patent App. 18/467,297, 2024 | | 2024 |
| Method for producing dna-edited eukaryotic cell, and kit used in the same T Mashimo, J Takeda, H Morisaka, K Yoshimi US Patent App. 18/467,356, 2024 | | 2024 |
| Therapeutic efficacy of allogenic haematopoietic stem cell transplantation from an appropriate sibling donor to a patient with subcutaneous panniculitis-like T-cell lymphoma … H Morisaka, H Sano, M Yamamoto, M Takaishi, H Nakajima, ... Journal of the European Academy of Dermatology and Venereology, 2024 | | 2024 |
| Method for producing DNA-edited eukaryotic cell, and kit used in the same T Mashimo, J Takeda, H Morisaka, K Yoshimi US Patent 11,807,869, 2023 | | 2023 |
| 850 Creation of cell models of dystrophic epidermolysis bullosa for therapeutic application of CRISPR-Cas3 H Morisaka, M Takaishi, S Sano, M Fujimoto Journal of Investigative Dermatology 143 (5), S146, 2023 | | 2023 |
| 436 Keratinocyte Regnase-1, a down-modulator of skin inflammation, contributes to protection from carcinogenesis through regulating COX-2 H Morisaka, M Takaishi, S Akira, S Sano Journal of Investigative Dermatology 142 (12), S256, 2022 | | 2022 |
| 283 Possibility of therapeutic application to autosomal dominant dystrophic epidermolysis bullosa using large deletion genome editing with CRISPR-Cas3 H Morisaka, K Yoshimi, Y Okuzaki, A Hotta, J Takeda, T Mashimo, S Sano Journal of Investigative Dermatology 140 (7), S34, 2020 | | 2020 |
| POSSIBLE APPLICATION OF BROAD AND UNIDIRECTIONAL GENOME EDITING USING THE NOVEL CRISPR-CAS3 SYSTEM FOR AUTOSOMAL DOMINANT EPIDERMOLYSIS BULLOSA H Morisaka, K Yoshimi, Y Okuzaki, A Hotta, J Takeda, T Mashimo, S Sano ACTA DERMATO-VENEREOLOGICA 100, 61-61, 2020 | | 2020 |
| A Case of IgA Vasculitis with Nephritis, Accompanied by DIC H MORISAKA, M TERAISHI, H SANO, T SHIGA, M YAMAMOTO, ... 西日本皮膚科 78 (2), 117-120, 2016 | | 2016 |
